Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or > 12 months: a subgroup analysis of the phase III NORA trial

	Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or > 12 months: a subgroup analysis of the phase III NORA trial
	Huang, Qidan 1; Wu, Xiaohua 2; Zhu, Jianqing 3; Wang, Danqing 4; Yang, Jiaxin 5; Wang, Jing 6; Wu, Lingying 7; Liu, Ziling 8; Gao, Yunong 9; Wang, Danbo 10
刊名	GYNECOLOGIC ONCOLOGY
	2021-08-01
卷号	162
ISSN号	0090-8258
资助项目	GlaxoSmithKline
WOS研究方向	Oncology ; Obstetrics & Gynecology
语种	英语
出版者	ACADEMIC PRESS INC ELSEVIER SCIENCE
WOS记录号	WOS:000687070800027
资助机构	GlaxoSmithKline
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/125099]
专题	中国科学院合肥物质科学研究院
作者单位	1.Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China 2.Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China 3.Univ Chinese Acad Sci, Canc Hosp, Beijing, Peoples R China 4.West China Second Univ Hosp, Chengdu, Peoples R China 5.Peking Union Med Coll Hosp, Beijing, Peoples R China 6.Hunan Canc Hosp, Changsha, Peoples R China 7.Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China 8.First Hosp Jilin Univ, Changchun, Peoples R China 9.Peking Univ Canc Hosp & Inst, Beijing, Peoples R China 10.China Med Univ, Canc Hosp, Shenyang, Liaoning, Peoples R China
推荐引用方式 GB/T 7714	Huang, Qidan,Wu, Xiaohua,Zhu, Jianqing,et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or > 12 months: a subgroup analysis of the phase III NORA trial[J]. GYNECOLOGIC ONCOLOGY,2021,162.
APA	Huang, Qidan.,Wu, Xiaohua.,Zhu, Jianqing.,Wang, Danqing.,Yang, Jiaxin.,...&Dong, Juan.(2021).Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or > 12 months: a subgroup analysis of the phase III NORA trial.GYNECOLOGIC ONCOLOGY,162.
MLA	Huang, Qidan,et al."Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or > 12 months: a subgroup analysis of the phase III NORA trial".GYNECOLOGIC ONCOLOGY 162(2021).